GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » Gross-Profit-to-Asset %

Kiadis Pharma NV (FRA:K3P) Gross-Profit-to-Asset % : 53.48% (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Kiadis Pharma NV's annualized Gross Profit for the quarter that ended in Dec. 2020 was €35.00 Mil. Kiadis Pharma NV's average Total Assets over the quarter that ended in Dec. 2020 was €65.44 Mil. Therefore, Kiadis Pharma NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2020 was 53.48%.


Kiadis Pharma NV Gross-Profit-to-Asset % Historical Data

The historical data trend for Kiadis Pharma NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Gross-Profit-to-Asset % Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only - - - - 24.60

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 53.48

Competitive Comparison of Kiadis Pharma NV's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Kiadis Pharma NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Gross-Profit-to-Asset % falls into.



Kiadis Pharma NV Gross-Profit-to-Asset % Calculation

Kiadis Pharma NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2020 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=17.5/( (79.502+62.762)/ 2 )
=17.5/71.132
=24.60 %

Kiadis Pharma NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2020 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2020 )/( (Total Assets (Q: Jun. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=35/( (68.122+62.762)/ 2 )
=35/65.442
=53.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2020) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Kiadis Pharma NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (FRA:K3P) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines